Claims
- 1. A human monoclonal antibody capable of neutralizing both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV).
- 2. The human monoclonal antibody of claim 1, wherein the antibody binds to an epitope present on glycoprotein F.
- 3. The human monoclonal antibody of claim 2, which is a Fab fragment.
- 4. The human monoclonal antibody of claim 3, wherein the monoclonal antibody has the binding specificity of an Fab fragment produced by ATCC 69071 or ATCC 69072.
- 5. The human monoclonal antibody of claim 3, wherein the monoclonal antibody is a Fab fragment produced by ATCC 69071 or ATCC 69072.
- 6. The human monoclonal antibody of claim 2, wherein the heavy chain comprises a CDR3 polypeptide sequence selected from the group consisting of:
- 7. A polynucleotide sequence encoding a human monoclonal antibody capable of neutralizing respiratory syncytial virus (RSV).
- 8. The polynucleotide sequence of claim 7, wherein the polynucleotide encodes an immunoglobulin heavy chain CDR3 polypeptide sequence selected from the group consisting of:
- 9. The polynucleotide sequence of claim 7, wherein the polynucleotide is DNA.
- 10. A host cell comprising the polynucleotide sequence of claim 7.
- 11. A biologically functional vector comprising the polynucleotide sequence of claim 7.
- 12. The method of detecting respiratory syncytial virus (RSV) comprising contacting a source suspected of containing RSV with a diagnostically effective amount of the monoclonal antibody of claim 1 and determining whether the monoclonal antibody binds to the source.
- 13. The method of claim 12, wherein the detecting is in vivo.
- 14. The method of claim 13, wherein the monoclonal antibody is detectably labeled with a label selected from the group consisting of a radioisotope and a paramagnetic label.
- 15. The method of claim 12, wherein the detecting is in vitro.
- 16. The method of claim 15, wherein the monoclonal antibody is detectably labeled with a label selected from the group of a radioisotope, a fluorescent compound, a colloidal metal, a chemiluminescent compound, a ioluminescent compound, and an enzyme.
- 17. The method of claim 15, wherein the monoclonal antibody is bound to a solid phase.
- 18. A method for providing passive immunotherapy to respiratory syncytial virus (RSV) disease in a human, comprising administering to the human an immunotherapeutically effective amount of the monoclonal antibody of claim 1.
- 19. The method of claim 18, wherein the passive immunotherapy is provided prophylactically.
- 20. The method of claim 18, wherein the disease is selected from the group consisting of pneumonia and bronchiolitis.
- 21. The method of claim 18, wherein the administering is by the respiratory tract or parenterally.
- 22. The method of claim 21, wherein the respiratory tract administration is by pulmonary aerosol.
- 23. The-method of claim 22, wherein the pulmonary aerosol comprises particles less than about 5 μm in diameter.
- 24. The method of claim 21 in which the material is administered as a liquid.
- 25. The method of claim 24, wherein the liquid is administered using a bronchoscope or artificial airway.
- 26. The method of claim 21, wherein the parenteral administration is by subcutaneous, intramuscular, intraperitoneal, intracavity, transdermal, or intravenous injection.
- 27. The method of claim 21, wherein the parenteral administration is by gradual perfusion.
- 28. The method of claim 27, wherein the gradual perfusion is by intravenous or peristaltic means.
- 29. The method of claim 18, wherein the imunotherapeutically effective amount is from about 0.01 mg/kg to about 300 mg/kg.
- 30. The method of claim 18, wherein the imunotherapeutically effective amount is from about 0.1 mg/kg to about 200 mg/kg.
- 31. The method of claim 18, wherein the imunotherapeutically effective amount is from about 0.2 mg/kg to about 20 mg/kg.
- 32. A method for providing passive immunotherapy to a viral mucosal disease in a host, comprising administering to the host an immunotherapeutically effective amount of a pulmonary aerosol of a Fab fragment which specifically binds and inhibits the virus, wherein the virus is capable of growth at the lumenal surface of the human respiratory tract.
- 33. The method of claim 32, wherein the virus is selected from the group consisting of respiratory syncytial virus, influenza virus, parainfluenza virus, rhinovirus, and coronavirus.
- 34. The method of claim 32, wherein the host is a human.
- 35. The method of claim 32, wherein the Fab fragment has the binding specificity of an Fab fragment produced by ATCC 69071 or ATCC 69072.
- 36. The method of claim 32, wherein the Fab fragment is an fab fragment produced by ATCC 69071 or ATCC 69072.
- 37. The method of claim 32, wherein the heavy chain of Fab fragment comprises a polypeptide sequence selected from the group consisting of:
- 38. A method for inducing active immunotherapy to respiratory syncytial virus (RSV) disease in a human which comprises administering to the human an immunogenically effective amount of an anti-idiotype antibody to the monoclonal antibody of claim 1.
- 39. A pharmaceutical composition comprising at least one dose of an immunotherapeutically effective amount of the monoclonal antibody of claim 1 in a pharmacological carrier.
- 40. A kit useful for the detection of respiratory syncytial virus (RSV) in a source suspected of containing RSV, the kit comprising carrier means being compartmentalized to receive in close confinement therein one or more containers comprising a container containing the monoclonal antibody of claim 1.
- 41. The monoclonal antibody, or fragment thereof, of claim 1 wherein the binding affinity for RSV is about 4×108M−1.
- 42. The monoclonal antibody of claim 1 wherein the antibody is a single chain antibody.
- 43. A human-derived epitope-binding peptide capable of neutralizing both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV).
- 44. The binding peptide of claim 43, wherein the peptide comprises a sequence selected from the group consisting of APIAPPYFDH (SEQ. I.D. 1) and HLPDYWNLDYTRFFYYMDV (SEQ. I.D. 2).
- 45. The binding peptide of claim 43, wherein the peptide binds to an epitope present of glycoprotein F.
- 46. A vector comprising DNA encoding the human antibody of claim 1, 3, 41 or 42.
- 47. A host cell comprising the vector of claim 46.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PCT/US93/08786 |
Sep 1993 |
WO |
|
Parent Case Info
[0001] This application is a continuation-in-part application of U.S. Ser. No. 07/945,515, filed Sep. 16, 1992.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08162102 |
Dec 1993 |
US |
Child |
08920100 |
Aug 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08920100 |
Aug 1997 |
US |
Child |
10768952 |
Jan 2004 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
07945515 |
Sep 1992 |
US |
Child |
08162102 |
Dec 1993 |
US |